Literature DB >> 22914367

High susceptibility for enterovirus infection and virus excretion features in Tunisian patients with primary immunodeficiencies.

Nadia Driss1, Imen Ben-Mustapha, Fethi Mellouli, Ahlem Ben Yahia, Henda Touzi, Mohamed Bejaoui, Mohamed Ben Ghorbel, Henda Triki, Mohamed-Ridha Barbouche.   

Abstract

To estimate the susceptibility to enterovirus infection and the frequency of long-term poliovirus excreters in Tunisian patients with primary immunodeficiencies (PIDs), enteroviruses were assessed in stool specimens of 82 patients with humoral, combined, and other PIDs. Isolated viruses were typed and intratyped by standard molecular techniques, and the whole VP1 region of poliovirus isolates was sequenced. Polioviruses were detected in 6 patients; all isolates were vaccine related. Five patients rapidly stopped excretion; one excreted a poliovirus type 1 isolate for several months, and the isolate accumulated up to 14 mutations in the VP1 region. Nonpolio enteroviruses were identified in 6 patients; 4 of them kept excreting the same strain for more than 6 months. The rate of enterovirus infection was 13.4% of the PID patients and 20.7% of those with an IgG defect; it greatly exceeded the rates generally found in Tunisian supposed-immunocompetent individuals (4.1% during the study period; P = 0.001 and P < 0.0001, respectively). Interestingly, patients with combined immunodeficiencies were at a higher risk for enterovirus infection than those with an exclusively B cell defect. A major histocompatibility complex (MHC) class II antigen expression defect was found in 54% of enterovirus-positive patients and in the unique long-term poliovirus excreter. The study results also suggest that substitutive immunoglobulin therapy may help clearance of a poliovirus infection and that most PID patients have the ability to stop poliovirus excretion within a limited period. However, the high susceptibility of these patients to enterovirus infection reinforces the need for enhanced surveillance of these patients until the use of oral poliovirus vaccine (OPV) is stopped.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22914367      PMCID: PMC3485882          DOI: 10.1128/CVI.00293-12

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  29 in total

1.  Pathogenesis of poliovirus infection in PVRTg mice: poliovirus replicates in peritoneal macrophages.

Authors:  A M Buisman; J A J Sonsma; M G S van Wijk; J P Vermeulen; P J Roholl; T G Kimman
Journal:  J Gen Virol       Date:  2003-10       Impact factor: 3.891

2.  Gut-homing (alpha(4)beta(7)(+)) Th1 memory responses after inactivated poliovirus immunization in poliovirus orally pre-immunized donors.

Authors:  Carsten Krieg; Reinhard Maier; Andreas Meyerhans
Journal:  J Gen Virol       Date:  2004-06       Impact factor: 3.891

Review 3.  Circulating vaccine-derived polioviruses: current state of knowledge.

Authors:  Olen M Kew; Peter F Wright; Vadim I Agol; Francis Delpeyroux; Hiroyuki Shimizu; Neal Nathanson; Mark A Pallansch
Journal:  Bull World Health Organ       Date:  2004-02-26       Impact factor: 9.408

4.  Advantages and disadvantages of killed and live poliomyelitis vaccines.

Authors:  J L Melnick
Journal:  Bull World Health Organ       Date:  1978       Impact factor: 9.408

5.  Search for poliovirus carriers among people with primary immune deficiency diseases in the United States, Mexico, Brazil, and the United Kingdom.

Authors:  Neal A Halsey; Jorge Pinto; Francisco Espinosa-Rosales; María A Faure-Fontenla; Edson da Silva; Aamir J Khan; A D Webster; Philip Minor; Glynis Dunn; Edwin Asturias; Hamidah Hussain; Mark A Pallansch; Olen M Kew; Jerry Winkelstein; Roland Sutter
Journal:  Bull World Health Organ       Date:  2004-01       Impact factor: 9.408

6.  Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man.

Authors:  Calman MacLennan; Glynis Dunn; Aarnoud P Huissoon; Dinakantha S Kumararatne; Javier Martin; Paula O'Leary; Ronald A Thompson; Husam Osman; Philip Wood; Philip Minor; David J Wood; Deenan Pillay
Journal:  Lancet       Date:  2004-05-08       Impact factor: 79.321

7.  Search for poliovirus long-term excretors among patients affected by agammaglobulinemia.

Authors:  Lucia Fiore; Alessandro Plebani; Gabriele Buttinelli; Stefano Fiore; Valentina Donati; Jill Marturano; Annarosa Soresina; Baldassarre Martire; Chiara Azzari; Giovanni Nigro; Fabio Cardinale; Antonino Trizzino; Claudio Pignata; Patrizia Alvisi; Elisa Anastasio; Grazia Bossi; Alberto G Ugazio
Journal:  Clin Immunol       Date:  2004-04       Impact factor: 3.969

8.  Molecular characterization of coxsackievirus B5 isolates.

Authors:  Dorra Rezig; Ahlem Ben Yahia; Hager Ben Abdallah; Olfa Bahri; Hinda Triki
Journal:  J Med Virol       Date:  2004-02       Impact factor: 2.327

Review 9.  Towards global poliomyelitis eradication: the successes and challenges for a developed country.

Authors:  N Wood; B Thorley
Journal:  J Paediatr Child Health       Date:  2003-12       Impact factor: 1.954

10.  Poliovirus-specific CD4+ Th1 clones with both cytotoxic and helper activity mediate protective humoral immunity against a lethal poliovirus infection in transgenic mice expressing the human poliovirus receptor.

Authors:  B P Mahon; K Katrak; A Nomoto; A J Macadam; P D Minor; K H Mills
Journal:  J Exp Med       Date:  1995-04-01       Impact factor: 14.307

View more
  18 in total

1.  Fatal Coxsackie meningoencephalitis in a patient with B-cell lymphopenia and hypogammaglobulinemia following rituximab therapy.

Authors:  Thamiris Palacios; Luther Bartelt; William Scheld; M Beatriz Lopes; Sarah M Kelting; Steven Holland; W Ian Lipkin; Phenix-Lan Quan; Larry Borish; Monica Lawrence
Journal:  Ann Allergy Asthma Immunol       Date:  2015-06-02       Impact factor: 6.347

2.  Enterovirus-Related Immune Reconstitution Inflammatory Syndrome (IRIS) Following Haploidentical Stem Cell Transplantation in an MHC Class II-Deficient Child.

Authors:  Ravi M Shah; Sheila Waugh; Khuen F Ng; Andrew R Gennery; Mary Slatter; Andrew J Cant
Journal:  J Clin Immunol       Date:  2017-05-16       Impact factor: 8.317

Review 3.  Clearing Vaccine-Derived Poliovirus Infection Following Hematopoietic Stem Cell Transplantation: a Case Report and Review of Literature.

Authors:  Mohammadreza Shaghaghi; Mona Irannejad; Hassan Abolhassani; Shohreh Shahmahmoodi; Amir Ali Hamidieh; Saeed Soleyman-Jahi; Reza Yazdani; Gholamreza Azizi; Asghar Aghamohammadi
Journal:  J Clin Immunol       Date:  2018-06-14       Impact factor: 8.317

Review 4.  Life-Threatening Infections Due to Live-Attenuated Vaccines: Early Manifestations of Inborn Errors of Immunity.

Authors:  Laura Pöyhönen; Jacinta Bustamante; Jean-Laurent Casanova; Emmanuelle Jouanguy; Qian Zhang
Journal:  J Clin Immunol       Date:  2019-05-23       Impact factor: 8.317

Review 5.  Emerging Infections and Pertinent Infections Related to Travel for Patients with Primary Immunodeficiencies.

Authors:  Kathleen E Sullivan; Hamid Bassiri; Ahmed A Bousfiha; Beatriz T Costa-Carvalho; Alexandra F Freeman; David Hagin; Yu L Lau; Michail S Lionakis; Ileana Moreira; Jorge A Pinto; M Isabel de Moraes-Pinto; Amit Rawat; Shereen M Reda; Saul Oswaldo Lugo Reyes; Mikko Seppänen; Mimi L K Tang
Journal:  J Clin Immunol       Date:  2017-08-07       Impact factor: 8.317

6.  Clinical, immunological and genetic findings of a large tunisian series of major histocompatibility complex class II deficiency patients.

Authors:  Imen Ben-Mustapha; Khaoula Ben-Farhat; Naouel Guirat-Dhouib; Emna Dhemaied; Beya Larguèche; Meriem Ben-Ali; Jalel Chemli; Jihène Bouguila; Lamia Ben-Mansour; Fethi Mellouli; Monia Khemiri; Mohamed Béjaoui; Mohamed-Ridha Barbouche
Journal:  J Clin Immunol       Date:  2013-01-13       Impact factor: 8.317

7.  Sequential asymptomatic enterovirus infections in a patient with major histocompatibility complex class II primary immunodeficiency.

Authors:  Nadia Driss; Fethi Mellouli; Ahlem Ben Yahia; Henda Touzi; Mohamed-Ridha Barbouche; Henda Triki; Mohamed Bejaoui
Journal:  J Clin Microbiol       Date:  2014-07-16       Impact factor: 5.948

8.  Vaccine-Derived Polioviruses and Children with Primary Immunodeficiency, Iran, 1995-2014.

Authors:  Mohammadreza Shaghaghi; Shohreh Shahmahmoodi; Hassan Abolhassani; Saeed Soleyman-Jahi; Leila Parvaneh; Sussan Mahmoudi; Zahra Chavoshzadeh; Reza Yazdani; Seyed Mohsen Zahraei; Mohsen Ebrahimi; Mohammad H Eslamian; Hamideh Tabatabaie; Maryam Yousefi; Yaghoob M Kandelousi; Aliasghar Oujaghlou; Nima Rezaei; Asghar Aghamohammadi
Journal:  Emerg Infect Dis       Date:  2016-10       Impact factor: 6.883

9.  Vaccine-associated paralytic poliomyelitis and BCG-osis in an immigrant child with severe combined immunodeficiency syndrome - Texas, 2013.

Authors:  Robert Trimble; Jane Atkins; Troy C Quigg; Cara C Burns; Gregory S Wallace; Mary Thomas; Anil T Mangla; Anthony J Infante
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-08-22       Impact factor: 17.586

10.  Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs.

Authors:  Radboud J Duintjer Tebbens; Mark A Pallansch; Kimberly M Thompson
Journal:  BMC Infect Dis       Date:  2015-09-17       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.